Fostair Asthma Industry Growth,SWOT Analysis to 2023

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with (Fostair (Asthma) – Forecast and Market Analysis to 2023) / report name in subject line and your contact details.

Researcher has released its new PharmaPoint Drug Evaluation report, "Fostair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Fostair, developed by Chiesi, is an FDC of the ICS beclomethasone dipropionate and the LABA formoterol fumarate. Beclomethasone dipropionate is a prodrug that is metabolized to two active metabolites. The 17-monopropionate metabolite has a 30-fold greater affinity for glucocorticoid receptors than its 21-monopropionate counterpart and inhibits the secretion of mediators involved in asthma. Beclomethasone dipropionate is marketed as a standalone product, Teva's QVAR. Formoterol fumarate is a highly selective LABA. It acts by increasing cAMP, which, in turn, leads to relaxation of the bronchial smooth muscle. This way, formoterol inhibits the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from the human lung. AstraZeneca markets formoterol as a standalone drug under the name of Oxis Turbuhaler. Other companies also market formoterol, one example being Novartis' Foradil.

Complete report is available @ http://www.reportsnreports.com/reports/298115-fostair-asthma-forecast-and-market-analysis-to-2023.html .

Scope

• Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Fostair including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Fostair for the top five countries from 2013 to 2023.
• Sales information covered for France, Germany, Italy, Spain and the UK.

Reasons to Buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Asthma
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Fostair performance
• Obtain sales forecast for Fostair from 2013-2023 in top five countries (France, Germany, Italy, Spain and the UK)

Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=298115 .

Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Fostair (beclomethasone dipropionate/formoterol fumarate)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Asthma Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in This Study
7.6 About the Authors
7.6.1 Author
7.6.2 Author/Reviewer
7.6.3 Reviewer
7.6.4 Global Head of Healthcare
7.7 About Researcher
7.8 Disclaimer

Request Sample of this report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=298115 .

(For Single User License: US$ 3495 And Corporate User License: US$ 10485)

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Fostair (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.